Clinical Trial

Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort

Study acronym: INSPIRE-CODA
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to compare the efficacy and safety of a Contezolid and Delamanid-Containing short regimen to standard longer regimen in Rifampicin-resistant pulmonary tuberculosis (RR-TB). The main questions it aims to answer are: * Is the efficacy of short regimen non-inferior to standard regimen? * Is the short regimen safe enough to replace the standard regimen? Participants will: * Be given with either short or standard regimen for RR-TB treatment * Be asked to complete the scheduled visit as planned.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-10-11; most recent amendment 2025-03-26.
Status change: Recruiting → Active, Not Recruiting 2025-03-26
Status change: Not Yet Recruiting → Recruiting 2024-03-13
Trial Details
NCT Number NCT06081361
Lead Sponsor Beijing Chest Hospital
Collaborators: National Medical Center for Infectious Diseases
Conditions Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
Enrollment 186 participants
Start Date 2023-12-22
Primary Completion 2026-10-01 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-01